Know Labs Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Know LabsDer Gewinn des Unternehmens wird voraussichtlich um 13.7% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 150.1% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich zurückgehen.

Wichtige Informationen

-13.7%

Wachstumsrate der Gewinne

-15.9%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	150.1%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	15 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NYSEAM:KNW - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
9/30/2026	6	-22	N/A	-20	1
9/30/2025	N/A	-19	N/A	-15	1
9/30/2024	N/A	-17	-13	-13	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-21	-11	-11	N/A
12/31/2023	N/A	-20	-11	-11	N/A
9/30/2023	N/A	-20	-10	-10	N/A
6/30/2023	N/A	-23	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	0	-19	-8	-8	N/A
9/30/2022	4	-20	-8	-7	N/A
6/30/2022	4	-22	-6	-5	N/A
3/31/2022	4	-26	-6	-5	N/A
12/31/2021	4	-25	-8	-7	N/A
9/30/2021	N/A	-25	-7	-7	N/A
6/30/2021	N/A	-22	-6	-6	N/A
3/31/2021	N/A	-18	-6	-5	N/A
12/31/2020	0	-16	-5	-5	N/A
9/30/2020	0	-14	-4	-4	N/A
6/30/2020	0	-12	-4	-4	N/A
3/31/2020	1	-12	-4	-4	N/A
12/31/2019	1	-10	-3	-3	N/A
9/30/2019	2	-8	-3	-3	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	3	-4	-2	-2	N/A
12/31/2018	4	-3	-1	-1	N/A
9/30/2018	4	-3	-1	-1	N/A
6/30/2018	5	-3	N/A	-1	N/A
3/31/2018	5	-2	N/A	-1	N/A
12/31/2017	5	-2	N/A	-1	N/A
9/30/2017	5	-4	N/A	-1	N/A
6/30/2017	5	-4	N/A	-2	N/A
3/31/2017	6	-3	N/A	-2	N/A
12/31/2016	6	-2	N/A	-3	N/A
9/30/2016	6	-2	N/A	-3	N/A
6/30/2016	6	-3	N/A	-2	N/A
3/31/2016	6	-4	N/A	-1	N/A
12/31/2015	6	-1	N/A	0	N/A
9/30/2015	6	-3	N/A	0	N/A
6/30/2015	7	0	N/A	-1	N/A
3/31/2015	7	1	N/A	-1	N/A
12/31/2014	8	-3	N/A	-2	N/A
9/30/2014	8	-1	N/A	-1	N/A
6/30/2014	8	-2	N/A	-2	N/A
3/30/2014	8	-6	N/A	-3	N/A
12/31/2013	8	-7	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KNW wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KNW wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KNW wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KNW wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Hohe Wachstumseinnahmen: KNW wird im nächsten Jahr voraussichtlich keine Einnahmen haben.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KNW in 3 Jahren voraussichtlich hoch sein wird

Know Labs Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Know Labs, Inc Announces Executive Appointments

Know Labs Receives Non Compliance Letter from NYSE American Regarding Sections 1003(a)(ii) and 1003(a)(iii)

High number of new and inexperienced directors

Know Labs, Inc. Announces Board and Committee Changes

Know Labs, Inc. has completed a Composite Units Offering in the amount of $3.445 million.

Know Labs, Inc., Annual General Meeting, Sep 26, 2024

Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal

Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study

Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International

Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting

Know Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study

Know Labs, Inc. Announces Board Appointments

Know Labs, Inc. Expands Board of Directors

Know Labs, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Know Labs, Inc., Annual General Meeting, Sep 22, 2023

Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal

Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring

Know Labs, Inc. Announces Changes to Executive Leadership Team

Know Labs, Inc. Announces Management Changes

Know Labs Common Stock Deleted from OTC Equity

Know Labs, Inc. has completed an IPO in the amount of $7.2 million.

Know Labs, Inc., Annual General Meeting, Sep 15, 2022

Know Labs, Inc. Announces Executive Appointments

Know Labs, Inc. Announces Executive Appointments

Know Labs Outlines Preparations for Pre-Submission Meeting with FDA

Know Labs, Inc. announced delayed 10-Q filing

Know Labs, Inc. Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™

Know Labs, Inc. Announces Introduction of New KnowU™ Diagnostic Device

Know Labs Receives New Patent for Its Non-Invasive Diagnostic Technology Platform, Bringing Patents Issued and Pending to Nearly 60

Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

Know Labs, Inc. announced that it has received $14.279 million in funding

Texas Biomedical Research Institute Issues Preliminary Results for Know Labs, Inc.'s Particle Bulb's Ability to Inactivate the SARS-CoV-2 Virus

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken